Replies to post #124382 on Anavex Life Sciences Corp (AVXL)

[F1ash]

ie. at a minimum, he should be able to escalate dosage on the "ongoing 25" to 50mg in case they were below it and didn't optimally respond, to then determine if observed effect matches Ariana's projections.

If I’m reading and understanding their previous poster correctly that seems very unlikely.

“These results closely reflect the practical course of the study where 25% of the patients remained on their initially allocated dose level of 50 mg while 75% of the total number of patients remained in the 30 mg dose level after five weeks of treatment.

http://www.anavex.com/my_uploads/New-Alzheimers-Drug-ANAVEX-2-73-Phase-2A-Study.pdf

I’ve never seen this discussed here before, but perhaps this is where the “low dose” patients come from?

It’s a bit confusing because apparently patients were on “between 10 and 50 mg and the charts show (low , med and high) concentrations.

Are all of the “low” those that were dropped from the 30 and 50 mg groups? The numbers would make sense if that were the case but, it seems unlikely more patients could be increased to 50 mg due to side effects. (Again, only if I understand the statement from the original poster presentation correctly.)

[Jonjones325]

This is an interesting thought. You are correct. Part C results are the validation of Ariana's analysis.

Hopefully we see some details at the CTAD. Choosing additional patients to replace the ones that dropped out using their data to select them would indeed be a homerun.

You would think Missling and the gang have explored this considering the amount of flexibility they have.

Secret early phase 3? That's a wild idea. Anything is possible.